p53 Apoptotic Pathway Molecules Are Frequently and Simultaneously Altered in Nonsmall Cell Lung Carcinoma

Cancer

Volumn 100, Issue 8, 2004, Pages 1673-1682

  Mori, Shoichi ^a   Ito, Genshi ^a   Usami, Noriyasu ^a   Yoshioka, Hiromu ^a   Ueda, Yuichi ^a   Kodama, Yoshinori ^a   Takahashi, Masahide ^a   Fong, Kwun M ^b   Shimokata, Kaoru ^a   Sekido, Yoshitaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Apoptosis; Mutation; Nonsmall cell lung carcinoma (NSCLC); p53

Indexed keywords

ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; PROTEINASE; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE AMPLIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METHYLATION; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; ZINC FINGERS;

EID: 11144354828     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20164     Document Type: Article

References (38)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
2. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1998;1378:F21-F59.
3. Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998;26:205-213.
4. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999;8:625-634.
5. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6:4055-4063.
6. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94-99.
7. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a is frequently lost in small cell lung cancer. Cancer Res. 1998;58:3926-3931.
8. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 1998;17:2779-2785.
9. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302-1308.
10. Gorgoulis VG, Zacharatos PV, Manolis E, et al. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. Br J Cancer. 1998;77:374-384.
11. ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002; 21:2750-2761.
12. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002;27:462-467.
13. Forgacs E, Biesterveld EJ, Sekido Y, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998;17:1557-1565.
14. Yokomizo A, Tindall DJ, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 1998;17:475-479.
15. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett. 2000;466:6-10.
16. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol. 1996;149:1941-1952.
17. Fleming MV, Guinee DG Jr., Chu WS, et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol. 1998;29:60-64.
18. Borner MM, Brousset P, Pfanner-Meyer B, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer. 1999;79:952-958.
19. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002;416:648-653.
20. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8:781-794.
21. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, Inc., 1997.
22. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. 3rd edition. Berlin: Springer-Verlag, 1999.
23. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene. 2001;20:4249-4257.
24. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1991;51:2416-2419.
25. Sekido Y, Sato M, Usami N, et al. Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor. Cancer Genet Cytogenet. 2002;137:33-42.
26. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15:2456-2466.
27. McCarty KS Jr., Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244s-4248s.
28. INK4a methylation and p53 mutational status. Cancer Res. 2000;60: 129-133.
29. INK4a and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21:4822-4829.
30. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996;13:1971-1981.
31. Fujita T, Kiyama M, Tomizawa Y, Kohno T, Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol. 1999;15:927-934.
32. Ahrendt SA, Halachmi S, Chow JT, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA. 1999;96:7382-7387.
33. Park MJ, Shimizu K, Nakano T, et al. Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet. 2003;141:5-13.
34. Gorgoulis VG, Rassidakis GZ, Karameris AM, et al. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Mod Pathol. 1996;9:544-554.
35. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 1999;96:6937-6941.
36. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001;98:11598-11603.
37. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178-1184.
38. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-3997.